Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 19,857

Document Document Title
WO/2019/002173A1
The present invention relates to a compound of formula (I): wherein the meanings for the various substituents are as disclosed in the description, having dual pharmacological activity towards both the α2δ subunit, in particular the α2...  
WO/2019/000494A1
Provided is a fluorene-based organic electroluminescent compound, having the following structure: The compound has good thermal stability, high luminous efficiency, and high luminous purity, and can be used for manufacturing organic elec...  
WO/2019/002074A1
The present invention provides PRMT5 inhibiting compounds of general formula (I). A compound of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, L1 and L2 are as defined herein, methods of preparing said compounds, intermediate ...  
WO/2019/001416A1
The present invention provides a thiazolinone heterocyclic compound and a preparation method, pharmaceutical composition, and application thereof. The present invention provides an application of the thiazolinone heterocyclic compound in...  
WO/2018/235966A1
The present invention provides a compound which has an excellent inhibitory activity on histone acetyltransferase of EP300 and/or CREBBP, or a pharmacologically acceptable salt of the compound. A compound represented by formula (1) or a ...  
WO/2018/233326A1
A hydrogen sulfide donor in an organic salt form and a preparation method therefor. The hydrogen sulfide donor is a salt structure formed by organic compounds with an alkaline structure and hydrogen sulfide. The hydrogen sulfide donor ha...  
WO/2018/235926A1
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...  
WO/2018/230528A1
Provided are a novel nitrocatechol derivative having COMT inhibitory effect and DDC inhibitory effect or a salt thereof and a medicinal composition comprising the same. A compound represented by general formula (1) or a pharmaceutically ...  
WO/2018/224060A1
The present invention relates to solid forms with an antimicrobial activity comprising a polysaccharide and triiodide, where the triiodide decomposition to iodide and volatile iodine is significantly suppressed by the presence of a stabi...  
WO/2018/221562A1
According to the present invention, it is found that dopamine D2-like receptor agonists acts on a dopamine D2-like receptor in an activated Th cell and thereby inhibits the production of Interleukin-8 (IL-8).  
WO/2018/221433A1
Provided is a novel compound, and a pharmaceutically acceptable salt thereof, that has an action of reducing blood sugar and the like, and that is useful as a therapeutic and/or preventive medicine for diseases such as diabetes. Provided...  
WO/2018/216823A1
Provided are novel compounds represented by the following general formula [1] or pharmaceutically acceptable salts thereof, that inhibit LpxC, as well as pharmaceutical drugs comprising those compounds or pharmaceutically acceptable salt...  
WO/2018/213140A1
Disclosed herein are compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (...  
WO/2018/213150A1
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mi...  
WO/2018/211090A1
The present invention pertains to the field of fluorescent labeling of proteins. In particular, the present invention relates to membrane-impermeable fluorogenic chromophores being capable of binding reversibly a functional derivative of...  
WO/2018/209010A1
The present invention is directed to a kit for evaluating on the skin of a patient the sensitivity to penicillin, comprising (A) a first vial containing a major determinant mixture, the major determinant mixture comprising benzylpenicill...  
WO/2018/202654A1
The present invention relates to a process for preparing optically active compounds of formula X and intermediates thereof, (formula X) wherein the variables of compound of formula X are as defined in the claims and the description.  
WO/2018/200498A1
The present invention relates to compositions and methods for determining the absolute configuration of D/L-cysteine and/or the enantiomeric composition of cysteine and/or the concentration of total cysteine in a sample. Uses of the comp...  
WO/2018/197541A1
The present invention relates to a process for preparing optically active compounds of formula X and intermediates thereof, X wherein the variables of compound of formula X are as defined in the claims or the description.  
WO/2018/199277A1
Provided are: a pharmaceutical composition containing a type I crystal of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3- benzothiazole, a type II crystal of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3- benzo...  
WO/2018/193385A1
The present invention relates to 4-substituted phenylamidine derivatives of the general formula (I), wherein R5-R6, ArA4, D, G, B, Q and an integer m have the meanings as defined in the description. The invention further relates to metho...  
WO/2018/195127A1
Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca2+-activated CI" channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A ...  
WO/2018/187845A1
The present invention relates to certain heterocyclic compounds of formula (1) that have the ability to inhibit lysine biosynthesis via the diaminopimelate biosynthesis pathway in certain organisms. As a result of this activity these com...  
WO/2018/191199A1
Small molecule covalent inhibitors of DCNl and compositions containing the same are disclosed. Methods of using the DCNl covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCNl provides a benefit, like ...  
WO/2018/188785A1
The invention concerns a compound, wherein the compound is a substance according to the following formula (I) wherein the ring A is a pyrrolidine, piperidine, morpholine, or imidazole residue or a substituted pyrrolidine, piperidine, mor...  
WO/2018/187414A1
The present disclosure provides compounds and methods for inhibiting mTORC2, as well as methods for treating cancers such as glioblastoma.  
WO/2018/186365A1
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...  
WO/2018/177970A1
The present invention relates to pyrimidinium compounds of formula (I), to the stereoisomers, salts, tautomers and N-oxides thereof, their mixtures and to compositions comprising such compounds or mixtures. The invention also relates to ...  
WO/2018/177865A1
The present invention relates to the use of compounds having an anti- heparanase activity of formu la [R - L1- Ar1- L - Ar]2- X, wherein X is selected from the group consisting of SO2, C1 -C4 a lkylene, linear or branched, and wherein Ζ...  
WO/2018/176343A1
Compounds of Formula (A), where the definition of the variables are as described in the description, as well as their preparation and uses, and pharmaceutical compositions comprising these compounds and their uses as modulators of dysfun...  
WO/2018/183411A1
Compounds of formula (I) as inhibitors of DCNl and compositions containing the same are disclosed. Methods of using the DCNl inhibitors in the treatment of diseases and conditions wherein inhibition of DCNl provides a benefit, like oxida...  
WO/2018/180716A1
The present invention provides a polymerizable compound production method that enables production of, in high yield, a polymerizable compound used for producing an optical film or the like. The polymerizable compound production method ac...  
WO/2018/178345A1
The present invention is directed to a salt of a compound of formula (I), R1 is halogen or methyl; X is methyl, OR2, or SR2; Y1, Y2 is CR3 or N, and one of Y1, Y2 is N and one of Y1, Y2 is CR3; R2 is methyl or ethyl; R3 is hydrogen or me...  
WO/2018/172423A1
The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p¸ q, L, ׇ, X and m are as defined herein. The compound...  
WO/2018/170165A1
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of condi...  
WO/2018/168778A1
Provided is a polymerizable compound useful for preparing a polymer that enables the production of a film, such as an optical film, having a good balance of lightness and saturation, and can improve inverse wavelength dispersibility on t...  
WO/2018/162505A1
The present invention relates to the tromethamine salt of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclop entane carboxylic acid, a process for obtaining said salt, combination products and pharmaceutical compositions compri...  
WO/2018/162364A1
The present invention refers to a process for a catalytic aryl transfer to rearrange the backbone of aromatic C-X bonds.  
WO/2018/163077A1
The invention relates to indanyl compounds, their pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising the same for the treatment, management and /or lessening severity of ...  
WO/2018/159515A1
Provided is a method for producing a pentafluorosulfanyl aromatic compound represented by general formula (3), Ar-(SF5)k, (in the formula, Ar is a substituted or unsubstituted aryl group or heteroaryl group, and k is an integer between 1...  
WO/2018/158137A1
The present invention provides a process to enhance the productivity such as yield of radioactive fluorine labeled flutemetamol. Provided is a process for producing a radioactive fluorine labeledflutemetamol, which comprises: (a) a step ...  
WO/2018/157813A1
The present invention relates to a series of tricyclic compounds and the use thereof as receptor agonists of sphingosine 1-phosphate subtype 1 (S1P1), and in particular relates to compounds as shown in formula (I) or pharmaceutically acc...  
WO/2018/155942A1
The present disclosure relates to a plurality of host materials and an organic electroluminescent device comprising the same. The organic electroluminescent device of the present disclosure can exhibit excellent lifespan characteristics ...  
WO/2018/155661A1
The present invention addresses the problem of providing thiazole compounds and herbicides containing said thiazole compounds. The present invention pertains to thiazole compounds represented by general formula (1): [in the formula, R1 a...  
WO/2018/153297A1
The present invention provides a novel ligand for the dopamine D3 receptor and a preparation method therefor. The compound, and a pharmaceutically acceptable salt and a pharmaceutical combination or a pharmaceutical preparation thereof a...  
WO/2018/151861A1
Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, pr...  
WO/2018/151470A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present disclosure is contained in an electro...  
WO/2018/149309A1
The present invention provides a crystal form of a 4-phenylthiazole derivative, a pharmaceutical composition comprising the same, a preparation method, and a use of the crystal form in preparing a drug for treating thrombocytopenia assoc...  
WO/2018/145217A1
This invention provides compound having a structure of Formula (I): (I) Uses of such compounds for treatment of ERG, FLI1, ETV4, or ETV1 -mediated indications, including cancer. Also provided are pharmaceutical composition and methods of...  
WO/2018/145118A1
Provided herein, inter alia, are methods of treating cancer in a subject, by administering COH29 ((N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihyd roxybenzamide)).  

Matches 1 - 50 out of 19,857